526 related articles for article (PubMed ID: 33971000)
1. VEXAS syndrome.
Grayson PC; Patel BA; Young NS
Blood; 2021 Jul; 137(26):3591-3594. PubMed ID: 33971000
[TBL] [Abstract][Full Text] [Related]
2. Vacuolization of hematopoietic precursors: an enigma with multiple etiologies.
Gurnari C; Pagliuca S; Durkin L; Terkawi L; Awada H; Kongkiatkamon S; Zawit M; Hsi ED; Carraway HE; Rogers HJ; Visconte V; Maciejewski JP
Blood; 2021 Jul; 137(26):3685-3689. PubMed ID: 33690844
[TBL] [Abstract][Full Text] [Related]
3. Adult-onset autoinflammation caused by somatic mutations in UBA1: A Dutch case series of patients with VEXAS.
van der Made CI; Potjewijd J; Hoogstins A; Willems HPJ; Kwakernaak AJ; de Sevaux RGL; van Daele PLA; Simons A; Heijstek M; Beck DB; Netea MG; van Paassen P; Elizabeth Hak A; van der Veken LT; van Gijn ME; Hoischen A; van de Veerdonk FL; Leavis HL; Rutgers A
J Allergy Clin Immunol; 2022 Jan; 149(1):432-439.e4. PubMed ID: 34048852
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic options in VEXAS syndrome: insights from a retrospective series.
Bourbon E; Heiblig M; Gerfaud Valentin M; Barba T; Durel CA; Lega JC; Barraco F; Sève P; Jamilloux Y; Sujobert P
Blood; 2021 Jul; 137(26):3682-3684. PubMed ID: 33619558
[No Abstract] [Full Text] [Related]
5. Characteristic bone marrow findings in patients with UBA1 somatic mutations and VEXAS syndrome.
Patel N; Dulau-Florea A; Calvo KR
Semin Hematol; 2021 Oct; 58(4):204-211. PubMed ID: 34802541
[TBL] [Abstract][Full Text] [Related]
6. Clinical Heterogeneity of the VEXAS Syndrome: A Case Series.
Koster MJ; Kourelis T; Reichard KK; Kermani TA; Beck DB; Cardona DO; Samec MJ; Mangaonkar AA; Begna KH; Hook CC; Oliveira JL; Nasr SH; Tiong BK; Patnaik MM; Burke MM; Michet CJ; Warrington KJ
Mayo Clin Proc; 2021 Oct; 96(10):2653-2659. PubMed ID: 34489099
[TBL] [Abstract][Full Text] [Related]
7. A clinical, histopathological, and molecular study of two cases of VEXAS syndrome without a definitive myeloid neoplasm.
Li P; Venkatachalam S; Ospina Cordona D; Wilson L; Kovacsovics T; Moser KA; Miles RR; Beck DB; George T; Tantravahi SK
Blood Adv; 2022 Jan; 6(2):405-409. PubMed ID: 34649277
[TBL] [Abstract][Full Text] [Related]
8. Somatic Mutations in
Beck DB; Ferrada MA; Sikora KA; Ombrello AK; Collins JC; Pei W; Balanda N; Ross DL; Ospina Cardona D; Wu Z; Patel B; Manthiram K; Groarke EM; Gutierrez-Rodrigues F; Hoffmann P; Rosenzweig S; Nakabo S; Dillon LW; Hourigan CS; Tsai WL; Gupta S; Carmona-Rivera C; Asmar AJ; Xu L; Oda H; Goodspeed W; Barron KS; Nehrebecky M; Jones A; Laird RS; Deuitch N; Rowczenio D; Rominger E; Wells KV; Lee CR; Wang W; Trick M; Mullikin J; Wigerblad G; Brooks S; Dell'Orso S; Deng Z; Chae JJ; Dulau-Florea A; Malicdan MCV; Novacic D; Colbert RA; Kaplan MJ; Gadina M; Savic S; Lachmann HJ; Abu-Asab M; Solomon BD; Retterer K; Gahl WA; Burgess SM; Aksentijevich I; Young NS; Calvo KR; Werner A; Kastner DL; Grayson PC
N Engl J Med; 2020 Dec; 383(27):2628-2638. PubMed ID: 33108101
[TBL] [Abstract][Full Text] [Related]
9. UBA1 and DNMT3A mutations in VEXAS syndrome. A case report and literature review.
Shaukat F; Hart M; Burns T; Bansal P
Mod Rheumatol Case Rep; 2022 Jan; 6(1):134-139. PubMed ID: 34480172
[TBL] [Abstract][Full Text] [Related]
10. VEXAS syndrome in dermatology.
Afsahi V; Christensen RE; Alam M
Arch Dermatol Res; 2023 Mar; 315(2):161-164. PubMed ID: 35201420
[TBL] [Abstract][Full Text] [Related]
11. Estimated Prevalence and Clinical Manifestations of UBA1 Variants Associated With VEXAS Syndrome in a Clinical Population.
Beck DB; Bodian DL; Shah V; Mirshahi UL; Kim J; Ding Y; Magaziner SJ; Strande NT; Cantor A; Haley JS; Cook A; Hill W; Schwartz AL; Grayson PC; Ferrada MA; Kastner DL; Carey DJ; Stewart DR
JAMA; 2023 Jan; 329(4):318-324. PubMed ID: 36692560
[TBL] [Abstract][Full Text] [Related]
12. Case Report: Genetic Double Strike: VEXAS and TET2-Positive Myelodysplastic Syndrome in a Patient With Long-Standing Refractory Autoinflammatory Disease.
Lötscher F; Seitz L; Simeunovic H; Sarbu AC; Porret NA; Feldmeyer L; Borradori L; Bonadies N; Maurer B
Front Immunol; 2021; 12():800149. PubMed ID: 35126364
[TBL] [Abstract][Full Text] [Related]
13. Somatic Mutations in UBA1 Define a Distinct Subset of Relapsing Polychondritis Patients With VEXAS.
Ferrada MA; Sikora KA; Luo Y; Wells KV; Patel B; Groarke EM; Ospina Cardona D; Rominger E; Hoffmann P; Le MT; Deng Z; Quinn KA; Rose E; Tsai WL; Wigerblad G; Goodspeed W; Jones A; Wilson L; Schnappauf O; Laird RS; Kim J; Allen C; Sirajuddin A; Chen M; Gadina M; Calvo KR; Kaplan MJ; Colbert RA; Aksentijevich I; Young NS; Savic S; Kastner DL; Ombrello AK; Beck DB; Grayson PC
Arthritis Rheumatol; 2021 Oct; 73(10):1886-1895. PubMed ID: 33779074
[TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics, disease trajectories and management of vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome: a systematic review.
Kouranloo K; Dey M; Almutawa J; Myall N; Nune A
Rheumatol Int; 2024 Jul; 44(7):1219-1232. PubMed ID: 38129348
[TBL] [Abstract][Full Text] [Related]
15. Thrombotic manifestations of VEXAS syndrome.
Groarke EM; Dulau-Florea AE; Kanthi Y
Semin Hematol; 2021 Oct; 58(4):230-238. PubMed ID: 34802545
[TBL] [Abstract][Full Text] [Related]
16. Looking beyond VEXAS: Coexistence of undifferentiated systemic autoinflammatory disease and myelodysplastic syndrome.
Oganesyan A; Hakobyan Y; Terrier B; Georgin-Lavialle S; Mekinian A
Semin Hematol; 2021 Oct; 58(4):247-253. PubMed ID: 34802547
[TBL] [Abstract][Full Text] [Related]
17. VEXAS within the spectrum of rheumatologic disease.
Koster MJ; Warrington KJ
Semin Hematol; 2021 Oct; 58(4):218-225. PubMed ID: 34802543
[TBL] [Abstract][Full Text] [Related]
18. Case Report: VEXAS Syndrome: From Mild Symptoms to Life-Threatening Macrophage Activation Syndrome.
Staels F; Betrains A; Woei-A-Jin FJSH; Boeckx N; Beckers M; Bervoets A; Willemsen M; Neerinckx B; Humblet-Baron S; Blockmans DE; Vanderschueren S; Schrijvers R
Front Immunol; 2021; 12():678927. PubMed ID: 34046042
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic stem cell transplantation as a curative therapeutic approach for VEXAS syndrome: a case report.
Loschi M; Roux C; Sudaka I; Ferrero-Vacher C; Marceau-Renaut A; Duployez N; Passeron T; Cluzeau T
Bone Marrow Transplant; 2022 Feb; 57(2):315-318. PubMed ID: 34999727
[TBL] [Abstract][Full Text] [Related]
20. [Clinical and genetic features of MDS associated with VEXAS syndrome].
Kunimoto H
Rinsho Ketsueki; 2024; 65(4):255-264. PubMed ID: 38684436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
